Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Mar 22;23(5):50.
doi: 10.1007/s11912-021-01041-x.

Role of Platinums in Triple-Negative Breast Cancer

Filipa Lynce  1 , Raquel Nunes  2
Affiliations
Review

Role of Platinums in Triple-Negative Breast Cancer

Filipa Lynce et al. Curr Oncol Rep. .

Abstract

Purpose of review: Platinum compounds are used in the treatment of various types of cancer. Here, we review the current role of cisplatin and carboplatin in the treatment of early stage and advanced triple-negative breast cancer (TNBC), and the use of biomarkers in predicting response to platinum therapy.

Recent findings: Addition of carboplatin to a neoadjuvant chemotherapy regimen can result in improvement in the pathological complete response rates. The long-term benefit of the addition of carboplatin to standard chemotherapy regimens remains unproven. Single-agent platinum is an option in the treatment of advanced breast cancer. BRCA1/2 mutations predicted benefit from platinums in advanced, but not early stage breast cancer. There are yet no biomarkers to predict response to platinum in sporadic TNBC. Platinum compounds are an option in the treatment of TNBC. Identification of biomarkers to select tumors most likely to derive benefit from these agents is still needed. Ongoing trials are exploring the role of platinum in the adjuvant setting and in combination with other agents, including immune checkpoint inhibitors.

Keywords: BRCA1/2 carriers; Biomarkers; Breast cancer; Carboplatin; Homologous recombination deficiency; Pathological complete response; Platinum; Triple-negative breast cancer.

PubMed Disclaimer

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
    1. Bardal SK, Waechter JE, Martin, DS. Applied pharmacology. Elsevier/Saunders. 2011
    1. Harrap KR. Preclinical studies identifying carboplatin as a viable cisplatin alternative. Cancer Treat Rev. 1985;12(Suppl A):21–33. https://doi.org/10.1016/0305-7372(85)90015-5 . - DOI - PubMed
    1. Rose WC, Schurig JE. Preclinical antitumor and toxicology profile of carboplatin. Cancer Treat Rev. 1985;12(Suppl A):1–19. https://doi.org/10.1016/0305-7372(85)90014-3 . - DOI - PubMed
    1. Lebwohl D, Canetta R. Clinical development of platinum complexes in cancer therapy: an historical perspective and an update. Eur J Cancer. 1998;34(10):1522–34. https://doi.org/10.1016/s0959-8049(98)00224-x . - DOI - PubMed
    1. Calvert AH, Harland SJ, Newell DR, Siddik ZH, Jones AC, McElwain TJ, et al. Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II. Cancer Chemoth Pharmacol. 1982;9(3):140–7. https://doi.org/10.1007/BF00257742 . - DOI

MeSH terms

LinkOut - more resources